Triple-Pill Strategy Slashes Recurrent Stroke Risk by 39% in Groundbreaking TRIDENT Trial

April 23, 2026

In a major leap forward for stroke recovery and long-term prevention, a global clinical trial has found that a single “polypill” containing low doses of three common blood pressure medications can dramatically reduce the risk of a second stroke. The results of the TRIDENT trial, published today in The New England Journal of Medicine, show that patients who survived an intracerebral hemorrhage (ICH)—the deadliest form of stroke—were 39% less likely to suffer a recurrence when treated with this triple-combination therapy compared to standard care.

The findings, first teased at the World Stroke Congress in late 2025 and finalized today, offer a pragmatic solution to one of the most persistent challenges in neurology: achieving and maintaining intensive blood pressure control in high-risk patients. For the millions of survivors worldwide, this “three-in-one” approach could mean the difference between independence and devastating disability.

A New Weapon Against the “Deadliest” Stroke

Intracerebral hemorrhage occurs when a weakened blood vessel bursts and bleeds into the brain. While it accounts for only about 10–15% of all strokes, it is disproportionately lethal, carrying a 30–50% mortality rate within the first month. For those who survive, the threat is far from over; they face a 3–5% annual risk of a repeat bleed—a rate significantly higher than that of ischemic stroke (caused by clots).

“These study results have the potential to mark a real shift in how we manage blood pressure following a stroke,” said Dr. Craig Anderson, lead investigator from The George Institute for Global Health in Sydney, Australia. “This single-pill triple combination helped patients reach target blood pressure levels that are often elusive in real-world settings.”

Inside the TRIDENT Trial: Design and Results

The TRIDENT trial was a rigorous, multicenter study involving 1,670 clinically stable ICH survivors with existing hypertension (systolic blood pressure between 130–160 mm Hg). The median age of participants was 58 years.

The experimental pill, known as GMRx2, combines three established medications at half their standard doses:

1. Telmisartan (20 mg): An angiotensin receptor blocker (ARB) that relaxes blood vessels.

2. Amlodipine (2.5 mg): A calcium channel blocker that prevents vessels from narrowing.

3. Indapamide (1.25 mg): A diuretic that helps the body eliminate excess salt and water.

By using low doses of three different classes of drugs, the pill targets blood pressure through multiple biological pathways simultaneously, minimizing side effects while maximizing efficacy.

Key Findings at a Glance

The data revealed a striking “Number Needed to Treat” (NNT) of approximately 27 to 36. This means that for every 30 or so patients treated with the triple pill over 2.5 years, one additional stroke is prevented—a metric considered highly cost-effective by public health standards.

Addressing the “Adherence Gap”

Current medical guidelines recommend keeping systolic blood pressure below 130 mm Hg for ICH survivors. However, achieving this is notoriously difficult. In many cases, patients must take multiple different pills at various times of the day, leading to “pill fatigue” and missed doses.

“The clinical message is clear: maintaining a systolic blood pressure of less than 130 mm Hg reduced the risk,” noted an editorial accompanying the study. However, experts pointed out that even in the triple-pill group, only 50% of patients hit that target, compared to 26% in the placebo group. While the pill significantly improved control, it highlights that some patients may require even more intensive management.

Dr. Shahidur Rahman, a neurologist not involved in the study, emphasized the specific impact on brain bleeds. “The 60% reduction in recurrent ICH specifically was particularly striking. In high-burden settings where medical follow-up is sparse, a simple, once-daily pill is a game-changer.”

Public Health and Global Impact

The implications for global health are profound, particularly in low- and middle-income countries where stroke rates are climbing. In regions like India, where hypertension prevalence exceeds 25%, a low-cost polypill could be integrated into national health programs to provide scalable prevention.

By simplifying the regimen, researchers estimate a potential 20–30% boost in patient compliance. For a survivor, swapping three or four separate prescriptions for one daily dose reduces the cognitive load of managing a chronic condition and may decrease the frequency of necessary doctor visits.

Limitations and the Path Forward

Despite the enthusiasm, the medical community remains cautious. The TRIDENT trial utilized a “run-in” phase, where all participants took the active pill for two weeks before the study officially began. This helps ensure that patients who have immediate adverse reactions are excluded, which may slightly inflate the perceived safety and efficacy compared to the general public.

Other considerations include:

• Age: The average participant age was 58; more research is needed to determine if the same benefits apply to patients over 75, who may be more prone to dizziness or falls from blood pressure drops.

• Individualization: Some critics argue that fixed-dose combinations make it harder for doctors to “tweak” individual components if a patient experiences a specific side effect, such as ankle swelling from amlodipine.

• Long-term Effects: While the 2.5-year results are robust, the long-term impact on cognitive decline and overall mortality remains a subject for future study.

Conclusion: Turning Down the Faucet

The TRIDENT trial reinforces a simple but vital truth in neurology: blood pressure is the primary lever we can pull to prevent brain injury. As Dr. Anderson phrased it, intensive control is like “turning down a faucet to prevent a flood.”

While the triple pill is not a “cure,” it represents a sophisticated evolution in delivery—making life-saving treatment easier to take, easier to prescribe, and significantly more effective at keeping the next stroke at bay.

Reference Section

• https://www.medscape.com/viewarticle/one-pill-three-meds-fewer-strokes-after-ich-trident-results-2026a1000crp

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.